Idera Pharmaceuticals - A Buying Opportunity Following The Fade by EXPstocktrader
April 16, 2014
If you have been following Idera Pharmaceuticals (IDRA), you know that they have been ramping up as one of the most cutting edge companies in the field of discovery and development of its TLR Antagonists, as well as synthetic DNA- and RNA- based drug candidates which I believe could radically change gene therapies in medicine today.
Abstract #2570 As Presented at AACR in San Diego, CA on April 7, 2014
In my review, the preclinical data is quite impressive and almost certainly provides a strong rationale for the phased studies being performed by Idera in ABC-DLBCL and Waldenstrom Macroglobulinemia. We are of course in the early stages, but what is most exciting about this poster is the proof of concept in its TLR Antagonists that are being used in its... In vitro Studies in MYD88 L265P - Positive ABC-DLBCL Cell Lines.
This question that I pose is exactly why I believe that Idera Pharmaceuticals has amassed what I would call the elite team of biotech leaders and investment bankers over the past several quarters. What I am referring to is Idera's highly gifted management team, it's board, leadership, and two main investment firms; Pillar Invest Corp. and Baker Brothers Advisors.